-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The aggregate cost of goods produced and sold and services rendered during the reporting period.
-
Summary
-
Kymera Therapeutics, Inc. quarterly/annual Cost of Revenue history and growth rate from 2022 to Q3 2025.
- Kymera Therapeutics, Inc. Cost of Revenue for the quarter ending September 30, 2025 was $2.76M, a 26.1% decline year-over-year.
- Kymera Therapeutics, Inc. Cost of Revenue for the twelve months ending September 30, 2025 was $43.7M.
- Kymera Therapeutics, Inc. annual Cost of Revenue for 2024 was $47.1M, a 40.1% decline from 2023.
- Kymera Therapeutics, Inc. annual Cost of Revenue for 2023 was $78.6M, a 67.8% increase from 2022.
Cost of Revenue, Trailing 12 Months (USD)
Cost of Revenue, Quarterly (USD)
Cost of Revenue, YoY Quarterly Growth (%)
Cost of Revenue, Annual (USD)
Cost of Revenue, YoY Annual Growth (%)